Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CNR2 | P34972 | 9/20 | 0.42 |
| ▸ | CNR1 | P21554 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | CFD | P00746 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095325 | 0.95 | CFD (0.43) | L3MBTL1RAB9AALDH1A1CNR2CNR1 | |
| SCHEMBL6096254 | 0.87 | CNR1 (0.47) | L3MBTL1RAB9AALDH1A1CNR2CNR1 | |
| SCHEMBL6095925 | 0.82 | SGMS2 (0.46) | L3MBTL1RAB9AALDH1A1CNR2CNR1 | |
| SCHEMBL6094565 | 0.81 | TAS1R3 (0.42) | L3MBTL1RAB9AALDH1A1CNR2CNR1 | |
| SCHEMBL5859099 | 0.81 | CNR2 (0.42) | L3MBTL1RAB9AALDH1A1CNR2CNR1 | |
| SCHEMBL6097214 | 0.81 | CFD (0.64) | RAB9AALDH1A1KMT2AHPGDCFD | |
| SCHEMBL6098091 | 0.80 | KMT2A (0.43) | ALDH1A1MEN1KMT2AHPGDCFD | |
| SCHEMBL5862115 | 0.80 | ROCK2 (0.41) | L3MBTL1RAB9AALDH1A1CNR2CNR1 | |
| SCHEMBL6097613 | 0.79 | KMT2A (0.47) | L3MBTL1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL6098348 | 0.79 | CCR5 (0.48) | RAB9AALDH1A1MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064124-B2 | NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-06-20 | — | — | US | claimed |
| US-7064124-B2 | NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-06-20 | — | — | US | disclosed |
| US-20040122244-A1 | Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1314712-A1 | NF-KAPPA-B INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT | Daiichi Suntory Pharma Co., Ltd. (JP) | 2003-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122244-A1 | Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient | NFKBIA, NFKB1, IKBKB | L3MBTL1 3418/4885RAB9A 3710/4885ALDH1A1 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.